Johnson & Johnson Releases Efficacy Results of Vaccine Candidate

Johnson & Johnson has released the results of its coronavirus vaccine.

In short, it protects against COVID-19, but not as effectively as the two inoculations already approved by the FDA. Late-stage trials showed the Johnson & Johnson candidate to be 66 percent effective overall, and 85 percent effective against "Severe" cases.

Johnson & Johnson said its late-stage trial in the U.S. and seven other countries showed an overall 66% effectiveness in its vaccine in preventing moderate to severe illness.

The first vaccine to be approved by the FDA from Pfizer-BioNTech was 95 percent effective in trials.

Moderna's candidate was 94 percent effective in trials and received its FDA approval a few weeks later.

Unlike the Pfizer-BioNTech and Moderna shots, which require two trips to the clinic, the Johnson & Johnson candidate requires only one dose.

Another vaccine being developed by Oxford/AstraZeneca has reported a 70 percent efficacy rate, but Germany has advised that individuals 65 years and older should avoid getting the shot.

https://townhall.com/tipsheet/cortneyobrien/2021/01/29/johnson--johnson-releases-efficacy-results-n2583907